ALK-Abelló A/S

LSE:0OIR Stock Report

Market Cap: DKK 35.7b

ALK-Abelló Valuation

Is 0OIR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0OIR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0OIR (DKK159.2) is trading below our estimate of fair value (DKK177.36)

Significantly Below Fair Value: 0OIR is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0OIR?

Key metric: As 0OIR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0OIR. This is calculated by dividing 0OIR's market cap by their current earnings.
What is 0OIR's PE Ratio?
PE Ratio45.5x
EarningsDKK 785.00m
Market CapDKK 35.72b

Price to Earnings Ratio vs Peers

How does 0OIR's PE Ratio compare to its peers?

The above table shows the PE ratio for 0OIR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.9x
HIK Hikma Pharmaceuticals
19x12.2%UK£4.3b
GSK GSK
21.7x23.2%UK£54.4b
ANCR Animalcare Group
31.5x5.3%UK£145.5m
AZN AstraZeneca
31.4x18.2%UK£160.5b
0OIR ALK-Abelló
45.5x21.5%DKK 35.7b

Price-To-Earnings vs Peers: 0OIR is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the peer average (25.9x).

Price to Earnings Ratio vs Industry

How does 0OIR's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0OIR 45.5xIndustry Avg. 19.5xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0OIR is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the European Pharmaceuticals industry average (19.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0OIR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0OIR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.5x
Fair PE Ratio28x

Price-To-Earnings vs Fair Ratio: 0OIR is expensive based on its Price-To-Earnings Ratio (45.5x) compared to the estimated Fair Price-To-Earnings Ratio (28x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0OIR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 162.52
DKK 185.17
+13.9%
11.2%DKK 215.00DKK 153.00n/a6
Dec ’25DKK 162.10
DKK 181.20
+11.8%
11.4%DKK 215.00DKK 153.00n/a5
Nov ’25DKK 163.44
DKK 177.00
+8.3%
9.3%DKK 200.00DKK 153.00n/a5
Oct ’25DKK 170.80
DKK 177.00
+3.6%
9.3%DKK 200.00DKK 153.00n/a5
Sep ’25DKK 179.00
DKK 168.60
-5.8%
15.3%DKK 200.00DKK 128.00n/a5
Aug ’25DKK 156.11
DKK 155.40
-0.5%
11.5%DKK 180.00DKK 128.00n/a5
Jul ’25DKK 150.76
DKK 155.40
+3.1%
11.5%DKK 180.00DKK 128.00n/a5
Jun ’25DKK 152.60
DKK 155.00
+1.6%
11.4%DKK 175.00DKK 126.00n/a5
May ’25DKK 130.60
DKK 132.75
+1.6%
7.6%DKK 145.00DKK 120.00n/a4
Apr ’25DKK 124.10
DKK 125.00
+0.7%
15.0%DKK 140.00DKK 94.00n/a4
Mar ’25DKK 130.30
DKK 120.75
-7.3%
16.5%DKK 140.00DKK 94.00n/a4
Feb ’25DKK 110.70
DKK 112.00
+1.2%
10.6%DKK 125.00DKK 94.00n/a4
Jan ’25DKK 100.30
DKK 110.75
+10.4%
9.6%DKK 120.00DKK 94.00n/a4
Dec ’24DKK 92.07
DKK 110.75
+20.3%
9.6%DKK 120.00DKK 94.00DKK 162.104
Nov ’24DKK 76.45
DKK 117.80
+54.1%
21.3%DKK 160.00DKK 89.00DKK 163.445
Oct ’24DKK 79.45
DKK 112.80
+42.0%
25.2%DKK 160.00DKK 85.00DKK 170.805
Sep ’24DKK 83.10
DKK 116.40
+40.1%
22.5%DKK 160.00DKK 85.00DKK 179.005
Aug ’24DKK 74.15
DKK 128.20
+72.9%
23.6%DKK 169.00DKK 95.00DKK 156.115
Jul ’24DKK 74.69
DKK 128.20
+71.6%
23.6%DKK 169.00DKK 95.00DKK 150.765
Jun ’24DKK 82.16
DKK 124.20
+51.2%
27.0%DKK 169.00DKK 90.00DKK 152.605
May ’24DKK 85.41
DKK 129.20
+51.3%
22.6%DKK 169.00DKK 100.00DKK 130.605
Apr ’24DKK 106.61
DKK 141.20
+32.4%
15.6%DKK 169.00DKK 107.00DKK 124.105
Mar ’24DKK 103.36
DKK 142.20
+37.6%
16.4%DKK 174.00DKK 107.00DKK 130.305
Feb ’24DKK 102.37
DKK 139.80
+36.6%
18.0%DKK 174.00DKK 105.00DKK 110.705
Jan ’24DKK 95.52
DKK 142.20
+48.9%
20.2%DKK 186.00DKK 105.00DKK 100.305
Dec ’23DKK 102.40
DKK 142.20
+38.9%
20.2%DKK 186.00DKK 105.00DKK 92.075

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 03:47
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALK-Abelló A/S is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Alexandru CogutBryan Garnier & Co
Jesper IlsoeCarnegie Investment Bank AB